Topic
pharmaceutical-research
7 stories related to this topic, newest first.
forbes.combusiness32 days ago
Simcere Pharmaceutical Signs Research Deal with Stanford Medicine on Lung Disease Therapy
Simcere Pharmaceutical Group Limited entered a collaboration agreement with Stanford Medicine on May 29, 2026, to fund early-stage research on a potential treatment for idiopathic pulmonary fibrosis. The company will provide funding and, if the study succeeds, will license the mo…
Nprai38 days ago
Ginkgo Bioworks Automates Biology Lab With AI and Robots, Raising Biosecurity Concerns
The Boston company, founded nearly two decades ago by four MIT graduate students, now runs an autonomous lab that completed more than 30,000 experiments in six months with AI assistance.
thehindubusinessline.comfinance39 days ago
Rezolute to Present Four Studies on Hyperinsulinism at Endocrine Society Meeting
Rezolute, Inc. will deliver one oral presentation and three poster presentations at the Endocrine Society annual meeting in Chicago from June 13-16, 2026. The presentations cover clinical trial results and outcomes data related to congenital and tumor-associated hyperinsulinism.
thehindubusinessline.comscience42 days ago
BPC-157, a Peptide Discovered in 1989, Faces FDA Advisory Review on Compounding Use
Predrag Sikiric's research on the 15-amino-acid peptide began in 1983 and reached an FDA advisory committee scheduled for this summer. The compound is now part of a U.S. policy debate on access to unapproved peptides.
manilatimes.netpolitics49 days ago
GENFIT Presents Seven Posters at EASL Congress 2026
GENFIT will present seven posters at the EASL Congress 2026 covering research on acute-on-chronic liver failure and real-world data. The company also noted upcoming meetings on ACLF definitions and governance.
benzinga.comfinance56 days ago
Sanofi Reports Phase 2 Results for Efdoralprin Alfa in Alpha-1 Antitrypsin Deficiency
Sanofi announced that its Phase 2 Elevaate study showed efdoralprin alfa normalized and maintained functional AAT levels in patients with alpha-1 antitrypsin deficiency. All key secondary endpoints were met and the treatment was well tolerated.
FI
nbcnews.comworld62 days ago
Daily Pill Maintains 70% of Weight Loss vs 38-50% on Placebo One Year After Stopping GLP-1 Injections
A new study shows patients taking daily orforglipron kept more than 70 percent of prior weight loss after one year off jabs, compared with 38-50 percent for those on placebo. The Eli Lilly drug, already available in the US at around $149 per month for the lowest dose, offers a ch…